thasso

Blog Archives

SEMA4D gene variant quadruples obesity risk in individuals of African descent

Posted on March 25, 2017 by by

thassodotcom Posted in Allelic Variant, Genetic Predisposition, New Research, Thasso Post, Theragenomic Medicine 1 Comment ↓

March 26, 2017 – There is ample evidence that the burden of obesity is not the same across ethnic groups. While diet and lifestyle play a large role in determining body weight, there is also a heritable component. Unfortunately, most prior studies that have evaluated the role of genes in obesity have looked mostly at people of European or Asian descent,

…

If you are obese, can you blame it on your genes?

Posted on February 13, 2017 by by

thassodotcom Posted in Allelic Variant, Genetic Background, New Research, Pediatrics, Thasso Post, Theragenomic Medicine No Comments ↓

February 13, 2017 – If you are obese (or plain out fat), can you blame it on your genes? Actually, in very many cases, the answer is a qualified yes. Or a maybe. Under certain circumstances. Researchers are moving towards a better understanding of some of the roots of obesity.

…

Tags: Brain Reward Gene, DRD4 Gene, DRD4 Repeat 7 Allelic Variant, Obesity, Plasticity Gene, Thasso Post, Theragenomic Medicine

Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity

Posted on May 8, 2016 by by

Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF Posted in PubMed Entry, Thasso Post, Theragenomic Medicine No Comments ↓

Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF

JAMA Dermatol 2016 Apr;

PMID: 27120802

Abstract

Importance: Psoriasis has been shown to be associated with overweight and type 2 diabetes mellitus. The genetic association is unclear.

…

Tags: Diabetes Type 2, Genetic Association, Obesity, Psoriasis, Twin Study

The weight-management drug Liraglutide (Saxenda) has just been approved by the FDA

Posted on December 25, 2014 by by

thassodotcom Posted in New Drug Approval, Thasso Post 5 Comments ↓

December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as hypertension,

…

Weight-management drug Contrave approved

Posted on September 13, 2014 by by

thassodotcom Posted in New Drug Approval, Thasso Post No Comments ↓

September 13, 2014 – The U.S. Food and Drug Administration approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.